共 47 条
[1]
Miller JR(2004)The importance of early diagnosis of multiple sclerosis J Manag Care Pharm 10 S4-S11
[2]
Baker D(2017)Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab JAMA Neurol 74 961-969
[3]
Herrod SS(2017)Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis EBioMedicine. 16 41-50
[4]
Alvarez-Gonzalez C(2020)Event-driven immunoprofiling predicts return of disease activity in alemtuzumab-treated multiple sclerosis Front Immunol 11 56-293
[5]
Giovannoni G(2015)Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes Ther Adv Neurol Disord 8 274-33
[6]
Schmierer K(2013)Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties MAbs. 5 22-91
[7]
Baker D(2017)Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses J Neuroimmunol 313 89-61
[8]
Marta M(2013)Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis Neurology. 80 55-2164
[9]
Pryce G(2014)Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity Neurology. 82 2158-undefined
[10]
Giovannoni G(2019)Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab Neurol Neuroimmunol Neuroinflamm 7 undefined-undefined